Phytosphingosine Alleviates Cigarette Smoke-Induced Bronchial Epithelial Cell Senescence in Chronic Obstructive Pulmonary Disease by Targeting the Free Fatty Acid Receptor 4

Abstract

Chronic obstructive pulmonary disease (COPD) is a complex and irreversible respiratory disorder with a poor prognosis and a lack of effective pharmaceutical treatment. Our previous metabolomics study identified phytosphingosine (PHS) as a key differential metabolite in COPD that is positively correlated with lung function. In this study, we investigated the bioactive effects of PHS on experimental COPD and its underlying mechanisms using cigarette smoke (CS)-induced mouse and cell models. We found that administering PHS improved CS-induced lung dysfunction, emphysema, and airway inflammation by reducing cellular senescence and the senescence-associated secretory phenotype in bronchial epithelium. Mechanistically, PHS interacted with the free fatty acid receptor 4 (FFAR4) and upregulated its expression, leading to the modulation of STIP1 homology and U-Box containing protein 1 (STUB1) downstream, which controlled the ubiquitination levels of P53 and mitigated cellular senescence. Moreover, both FFAR4 overexpression through intratracheal injection of adeno-associated virus and the administration of the FFAR4 agonist TUG891 showed therapeutic effects on CS-induced lung damage. Our results highlight the beneficial impacts of PHS in experimental COPD mediated through the FFAR4 receptor, protecting against CS-induced bronchial epithelial cell senescence and suggesting PHS as a promising therapeutic agent for COPD.

Keywords

cellular senescence / chronic obstructive pulmonary disease / cigarette smoke / free fatty acid receptor 4 / phytosphingosine

References

[1] R. B. Werder, X. Zhou, M. H. Cho, and A. A. Wilson, “Breathing New Life Into the Study of COPD With Genes Identified From Genome-Wide Association Studies,” European Respiratory Review 33, no. 172 (2024): 240019.

[2] Collaborators GBDCoD, "Global Burden of 288 Causes of Death and Life Expectancy Decomposition in 204 Countries and territories and 811 Subnational Locations, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021," Lancet 403, no. 10440 (2024): 2100-2132.

[3] A. Agusti, B. R. Celli, G. J. Criner, et al., “Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary,” Archivos De Bronconeumologia 59, no. 4 (2023): 232-248.

[4] P. Jarhyan, A. Hutchinson, D. Khaw, D. Prabhakaran, and S. Mohan, “Prevalence of Chronic Obstructive Pulmonary Disease and Chronic Bronchitis in Eight Countries: A Systematic Review and Meta-Analysis,” Bulletin of the World Health Organization 100, no. 3 (2022): 216-230.

[5] W. MacNee, “Is Chronic Obstructive Pulmonary Disease an Accelerated Aging Disease,” Annals of the American Thoracic Society 13 (2016): S429-S437.

[6] N. Mercado, K. Ito, and P. J. Barnes, “Accelerated Ageing of the Lung in COPD: New Concepts,” Thorax 70, no. 5 (2015): 482-489.

[7] W. Gao, L. Li, Y. Wang, et al., “Bronchial Epithelial Cells: The Key Effector Cells in the Pathogenesis of Chronic Obstructive Pulmonary Disease?,” Respirology (Carlton, Vic) 20, no. 5 (2015): 722-729.

[8] D. Munoz-Espin and M. Serrano, “Cellular Senescence: From Physiology to Pathology,” Nature Reviews Molecular Cell Biology 15, no. 7 (2014): 482-496.

[9] Y. Zhan, Q. Huang, Z. Deng, et al., “DNA Hypomethylation-Mediated Upregulation of GADD45B Facilitates Airway Inflammation and Epithelial Cell Senescence in COPD,” Journal of Advanced Research 68 (2025): 201-214.

[10] N. Herranz and J. Gil, “Mechanisms and Functions of Cellular Senescence,” Journal of Clinical Investigation 128, no. 4 (2018): 1238-1246.

[11] D. J. Adamko, P. Nair, I. Mayers, R. T. Tsuyuki, S. Regush, and B. H. Rowe, “Metabolomic Profiling of Asthma and Chronic Obstructive Pulmonary Disease: A Pilot Study Differentiating Diseases,” Journal of Allergy and Clinical Immunology 136, no. 3 (2015): 571-580.

[12] S. Naz, J. Kolmert, M. Yang, et al., “Metabolomics Analysis Identifies Sex-Associated Metabotypes of Oxidative Stress and the Autotaxin-lysoPA Axis in COPD,” European Respiratory Journal 49, no. 6 (2017): 1602322.

[13] A. M. van der Does, M. Heijink, O. A. Mayboroda, et al., “Dynamic Differences in Dietary Polyunsaturated Fatty Acid Metabolism in Sputum of COPD Patients and Controls,” Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology 1864, no. 3 (2019): 224-233.

[14] Q. Huang, X. Wu, Y. Gu, et al., “Detection of the Disorders of Glycerophospholipids and Amino Acids Metabolism in Lung Tissue from Male COPD Patients,” Frontiers in Molecular Biosciences 9 (2022): 9839259.

[15] A. Ben Anes, H. Ben Nasr, Z. Tabka, O. Tabka, M. Zaouali, and K. Chahed, “Plasma Lipid Profiling Identifies Phosphatidylcholine 34:3 and Triglyceride 52:3 as Potential Markers Associated With Disease Severity and Oxidative Status in Chronic Obstructive Pulmonary Disease,” Lung 200, no. 4 (2022): 495-503.

[16] A. Ota, H. Morita, T. Naganuma, et al., “Bifunctional DEGS2 Has Higher Hydroxylase Activity Toward Substrates With Very-Long-Chain Fatty Acids in the Production of Phytosphingosine Ceramides,” Journal of Biological Chemistry 299, no. 4 (2023): 104603.

[17] Q. Cai, M. Chen, B. Wang, J. Wang, L. Xia, and J. Li, “Phytosphingosine Inhibits the Growth of Lung Adenocarcinoma Cells by Inducing G2/M-Phase Arrest, Apoptosis, and Mitochondria-Dependent Pathway Cell Death in Vitro and in Vivo,” Chemico-Biological Interactions 387 (2024): 110795.

[18] L. Li, T. Li, X. Liang, et al., “A Decrease in Flavonifractor Plautii and Its Product, Phytosphingosine, Predisposes Individuals With Phlegm-Dampness Constitution to Metabolic Disorders,” Cell Discovery 11, no. 1 (2025): 25.

[19] B. H. Kim, J. M. Lee, Y. G. Jung, S. Kim, and T. Y. Kim, “Phytosphingosine Derivatives Ameliorate Skin Inflammation by Inhibiting NF-kappaB and JAK/STAT Signaling in Keratinocytes and Mice,” Journal of Investigative Dermatology 134, no. 4 (2014): 1023-1032.

[20] S. B. Kwon, S. An, M. J. Kim, “Phytosphingosine-1-phosphate and Epidermal Growth Factor Synergistically Restore Extracellular Matrix in Human Dermal Fibroblasts in Vitro and in Vivo,” International Journal of Molecular Medicine 39, no. 3 (2017): 741-748.

[21] T. Nagasawa, H. Nakamichi, Y. Hama, S. Higashiyama, Y. Igarashi, and S. Mitsutake, “Phytosphingosine Is a Novel Activator of GPR120,” Journal of Biochemistry 164, no. 1 (2018): 27-32.

[22] A. T. Naito, S. Okada, T. Minamino, et al., “Promotion of CHIP-Mediated p53 Degradation Protects the Heart From Ischemic Injury,” Circulation Research 106, no. 11 (2010): 1692-1702.

[23] C. Sisoula, V. Trachana, C. Patterson, and E. S. Gonos, “CHIP-Dependent p53 Regulation Occurs Specifically During Cellular Senescence,” Free Radical Biology and Medicine 50, no. 1 (2011): 157-165.

[24] J. Gea, C. J. Enriquez-Rodriguez, and B. Agranovich, and S. Pascual-Guardia, “Update on Metabolomic Findings in COPD Patients,” ERJ Open Research 9, no. 5 (2023): 00180-2023.

[25] C. I. Cruickshank-Quinn, S. Jacobson, G. Hughes, et al., “Metabolomics and Transcriptomics Pathway Approach Reveals Outcome-Specific Perturbations in COPD,” Scientific Reports 8, no. 1 (2018): 17132.

[26] E. Mastej, L. Gillenwater, Y. Zhuang, K. A. Pratte, R. P. Bowler, and K. Kechris, “Identifying Protein-Metabolite Networks Associated With COPD Phenotypes,” Metabolites 10, no. 4 (2020): 124.

[27] Q. Chen, R. S. Deeb, Y. Ma, M. R. Staudt, R. G. Crystal, and S. S. Gross, “Serum Metabolite Biomarkers Discriminate Healthy Smokers From COPD Smokers,” PLoS ONE 10, no. 12 (2015): e0143937.

[28] G. Frigerio, R. Mercadante, L. Campo, et al., “Urinary Biomonitoring of Subjects With Different Smoking Habits. Part II: An Untargeted Metabolomic Approach and the Comparison With the Targeted Measurement of Mercapturic Acids,” Toxicology Letters 329 (2020): 56-66.

[29] M. Zhao, K. Fan, J. Wang, et al., “Lipidomic Analysis Reveals the Effect of Passive Smoking on Facial Skin Surface Lipid in Females,” Chemistry and Physics of Lipids 247 (2022): 105228.

[30] H. Zhu, A. S. Abdullah, J. He, et al., “Untargeted Urinary Metabolomics and Children's Exposure to Secondhand Smoke: The Influence of Individual Differences,” International Journal of Environmental Research and Public Health 18, no. 2 (2021): 710.

[31] L. F. Eggers, J. Muller, C. Marella, et al., “Lipidomes of Lung Cancer and Tumour-Free Lung Tissues Reveal Distinct Molecular Signatures for Cancer Differentiation, Age, Inflammation, and Pulmonary Emphysema,” Scientific Reports 7, no. 1 (2017): 11087.

[32] E. V. Berdyshev, K. A. Serban, K. S. Schweitzer, I. A. Bronova, A. Mikosz, and I. Petrache, “Ceramide and Sphingosine-1 Phosphate in COPD Lungs,” Thorax (2021): thoraxjnl-2020-215892.

[33] N. Kondo, Y. Ohno, M. Yamagata, et al., “Identification of the Phytosphingosine Metabolic Pathway Leading to Odd-Numbered Fatty Acids,” Nature Communications 5 (2014): 55338.

[34] K. Koike, E. V. Berdyshev, R. P. Bowler, et al., “Bioactive Sphingolipids in the Pathogenesis of Chronic Obstructive Pulmonary Disease,” Annals of the American Thoracic Society 15, no. 4 (2018): S249-S252.

[35] K. J. Diab, J. J. Adamowicz, K. Kamocki, et al., “Stimulation of Sphingosine 1-Phosphate Signaling as an Alveolar Cell Survival Strategy in Emphysema,” American Journal of Respiratory and Critical Care Medicine 181, no. 4 (2010): 344-352.

[36] K. Mizumura, M. J. Justice, K. S. Schweitzer, et al., “Sphingolipid Regulation of Lung Epithelial Cell Mitophagy and Necroptosis During Cigarette Smoke Exposure,” FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 32, no. 4 (2018): 1880-1890.

[37] D. N. Petrusca, Y. Gu, J. J. Adamowicz, et al., “Sphingolipid-Mediated Inhibition of Apoptotic Cell Clearance by Alveolar Macrophages,” Journal of Biological Chemistry 285, no. 51 (2010): 40322-40332.

[38] M. T. Park, M. J. Kim, Y. H. Kang, et al., “Phytosphingosine in Combination With Ionizing Radiation Enhances Apoptotic Cell Death in Radiation-Resistant Cancer Cells Through ROS-Dependent and -Independent AIF Release,” Blood 105, no. 4 (2005): 1724-1733.

[39] M. Takahashi, K. Izawa, M. Urai, et al., “The Phytosphingosine-CD300b Interaction Promotes Zymosan-Induced, Nitric Oxide-Dependent Neutrophil Recruitment,” Science Signaling 12, no. 564 (2019): eaar5514.

[40] D. K. Breslow, “Sphingolipid Homeostasis in the Endoplasmic Reticulum and Beyond,” Cold Spring Harbor Perspectives in Biology 5, no. 4 (2013): a013326.

[41] R. Xu, P. Antwi Boasiako, and C. Mao, “Alkaline Ceramidase Family: The First Two Decades,” Cellular Signalling 78 (2021): 109860.

[42] T. Nagasawa, M. Horitani, S. I. Kawaguchi, S. Higashiyama, Y. Hama, and S. Mitsutake, “The Molecular Mechanism of Phytosphingosine Binding to FFAR4/GPR120 Differs From That of Other Fatty Acids,” FEBS Open Bio 11, no. 11 (2021): 3081-3089.

[43] K. I. Hilgendorf, C. T. Johnson, A. Mezger, et al., “Omega-3 Fatty Acids Activate Ciliary FFAR4 to Control Adipogenesis,” Cell 179, no. 6 (2019): 1289-1305.e21.

[44] T. T. Wei, L. T. Yang, F. Guo, et al., “Activation of GPR120 in Podocytes Ameliorates Kidney Fibrosis and Inflammation in Diabetic Nephropathy,” Acta Pharmacologica Sinica 42, no. 2 (2021): 252-263.

[45] L. Yang, B. Wang, F. Guo, et al., “FFAR4 Improves the Senescence of Tubular Epithelial Cells by AMPK/SirT3 Signaling in Acute Kidney Injury,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 384.

[46] H. L. Ou and B. Schumacher, “DNA Damage Responses and p53 in the Aging Process,” Blood 131, no. 5 (2018): 488-495.

[47] P. J. Barnes, J. Baker, and L. E. Donnelly, “Cellular Senescence as a Mechanism and Target in Chronic Lung Diseases,” American Journal of Respiratory and Critical Care Medicine 200, no. 5 (2019): 556-564.

[48] E. Kevei and T. Hoppe, “Ubiquitin Sets the Timer: Impacts on Aging and Longevity,” Nature Structural & Molecular Biology 21, no. 4 (2014): 290-292.

[49] T. Min, M. Bodas, S. Mazur, and N. Vij, “Critical Role of Proteostasis-Imbalance in Pathogenesis of COPD and Severe Emphysema,” Journal of Molecular Medicine 89, no. 6 (2011): 577-593.

[50] M. L. Koloko Ngassie, C. A. Brandsma, R. Gosens, Y. S. Prakash, and J. K. Burgess, “The Stress of Lung Aging: Endoplasmic Reticulum and Senescence Tete-a-Tete,” Physiology 36, no. 3 (2021): 150-159.

[51] P. P. Cheng, F. Yu, S. J. Chen, et al., “PM2.5 Exposure-Induced Senescence-Associated Secretory Phenotype in Airway Smooth Muscle Cells Contributes to Airway Remodeling,” Environmental Pollution 347 (2024): 123674.

[52] S. Duan, N. Wang, L. Huang, et al., “NLRP3 Inflammasome Activation Involved in LPS and Coal Tar Pitch Extract-Induced Malignant Transformation of Human Bronchial Epithelial Cells,” Environmental Toxicology 34, no. 5 (2019): 585-593.

[53] Y. Zhan, J. Chen, J. Wu, et al., “Human Epididymis Protein 4 Aggravates Airway Inflammation and Remodeling in Chronic Obstructive Pulmonary Disease,” Respiratory Research 23, no. 1 (2022): 120.

[54] T. Wang, X. Du, Z. Wang, et al., “p55PIK Deficiency and Its NH(2)-Terminal Derivative Inhibit Inflammation and Emphysema in COPD Mouse Model,” American Journal of Physiology Lung Cellular and Molecular Physiology 321, no. 1 (2021): L159-L173.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.